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Abstract
Exposure to protein allergen epicutaneously, inducing a Th2-dominant immune response, sensitizes
the host to the development of atopic disease. Antigen-driven bystander effect demonstrates that
polarized T cells could instruct naïve T cells to differentiate into T cells with similar phenotype. In
this study, we aimed to determine the contribution of antigen-driven bystander effect on
epicutaneous sensitization with a newly introduced protein allergen. BALB/c mice were immunized
intraperitoneally with BSA emulsified in alum, known to induce a Th2 response, three weeks before
given BSA and OVA epicutaneously. Lymph node cells from these mice restimulated with OVA
secreted higher levels IL-4, IL-5 and IL-13 as compared with cells from mice without BSA
immunization. In addition, BALB/c mice immunized subcutaneously with BSA emulsified in
complete Freund's adjuvant, known to induce a Th1-predominant response, also induced higher
Th1 as well as Th2 cytokine response when restimulated with OVA as compared with mice without
immunization. We demonstrated that subcutaneous immunization with BSA in CFA induced Th2
as well as Th1 response. The threshold of epicutaneous sensitization to OVA was also reduced,
possibly due to increased expressions of IL-4 and IL-10 in the draining lymph nodes during the early
phase of sensitization. In conclusion, antigen-driven bystander effect, whether it is of Th1- or Th2-
predominant nature, can accelerate epicutaneous sensitization by a newly introduced protein
allergen. These results provide a possible explanation for mono- to poly-sensitization spread
commonly observed in atopic children.
Background
In the past several decades, there has been a progressive
increase in the prevalence of atopic disease and an associ-
ated increase in the cost of medical management [1].
Atopic diseases are manifested as atopic dermatitis (AD),
asthma, and allergic rhinitis. Atopy is associated with the
expression of allergen-specific immune response charac-
terized by the production of Th2 cytokines such as IL-4,
IL-5, and IL-13; elevated IgE production; and eosi-
nophilia. In contrast, non-atopic individuals display pre-
dominant Th1 immune response characterized by the
production of IFN-. Genetics predisposition and expo-
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Th2 immune response, contribute to the pathogenesis of
atopic diseases [2].
AD is often the first clinical manifestation of an atopic
triad and is the beginning of the "atopic march" [3]. How-
ever, the route of sensitization by an allergen that results
in AD is still unclear. There is compelling evidence to
show that epicutaneous exposure to a protein allergen is
one of the important routes to sensitize the host for AD
and other atopic diseases [4]. By the presence of cutane-
ous lymphocyte-associated antigen (CLA)-positive T cells,
it is shown in humans, that T cells are primed or reacti-
vated in the skin or its draining lymph nodes (LNs) [5,6].
In AD patients, the increased frequency of prior activation
and secretion of type 2 cytokines, as well as higher prolif-
eration response to allergen, are largely confined to a CLA-
positive subset [7-9]. Moreover, T cell receptor skewing is
only detectable within the CLA-positive subset of T cells
from those subjects from whom superantigen-secreting,
skin-dwelling bacteria could be identified [10]. The recent
demonstration of the expression of CLA by CD8 T cells
specific for a skin-tropic, but not non-skin-tropic, virus
further supports this concept [11]. We and others have
demonstrated in an atopic dermatitis animal model, that
epicutaneous exposure of protein antigen induces a pre-
dominant Th2 response with high IgE production [12,13].
Furthermore, epicutaneous sensitization with protein
antigen induces AD-like skin lesions and development of
asthma [14]. The epicutaneously-induced Th2 response
requires IL-10 and IL-13 [15,16], while down-regulation
of the response is mediated by C3a, cyclooxygenase-2,
and skin scratching [17-19].
It has been demonstrated that through an antigen-driven
bystander effect, polarized T cells instruct naïve T cells to
differentiate into T cells with a similar phenotype. This
bystander effect is observed only when the challenge inoc-
ulum contains both the original antigen and a newly
introduced antigen. This effect was initially shown to be a
mechanism of antigen-driven peripheral tolerance after
oral administration of antigens, and it can protect rats
from developing experimental autoimmune encephalo-
myelitis [20]. Adoptive co-transfer of two populations of
T-cell receptor transgenic T cells of different specificities
demonstrated that polarized Th1 or Th2 effector cells can
instruct naïve T cells to differentiate into Th1 or Th2 cells,
respectively [21]. Subsequently, study of a murine asthma
model revealed that an ongoing Th2 response can induce
antigen-specific Th2 response to a new antigen, a process
termed "collateral priming" [22]. Further exploration of
the underlying mechanisms of the antigen-driven
bystander effect has demonstrated that conversion of a
naïve T cell occurs only when it interacts with the same
APC as the memory T cell, and that the orally immunized
memory T cells use IL-4 and IL-10 to "educate" APCs,
which in turn induce naïve T cells to produce the same
cytokines as those produced by the orally immunized
memory T cells [23]. In this present study, we demon-
strated that antigen-driven bystander effect, despite its
Th1- or Th2-predominant nature, accelerates epicutane-
ous sensitization with a new protein antigen.
Materials and methods
Mice and reagents
Six to 10-week-old female BALB/c and TCR-OVA-
DO11.10 mice were purchased from the animal center of
National Taiwan University Collage of Medicine and kept
in a specific pathogen-free environment. All animal exper-
iments were approved by the animal care committee of
the Medical College of National Taiwan University. OVA
(Grade V), BSA, CFA, and 4-nitrophenyl phosphate
(pNPP) were purchased from Sigma-Aldrich (St. Louis,
MO). Alum adjuvant was purchased from Pierce (Rock-
ford, IL) and carboxyfluorescein succinimidyl ester
(CFSE) was obtained from Invitrogen (Carlsbad, CA).
Capture and biotin-conjugated detecting antibodies for
IFN-, IL-4, IL-5 used in the ELISA were from PharMingen
(San Diego, CA). Streptavidine-alkaline phosphatase was
purchased from Southern Biotechnology (Birmingham,
AL). The murine IL-13 ELISA kit purchased from R&D sys-
tems (Minneapolis, MN) was used for determination of
the IL-13 content of supernatants.
Sensitization
Mice were sensitized as previously described [24]. Briefly,
20 l of OVA (100 mg/ml or serial dilutions) and 20 l of
BSA (100 mg/ml) were placed on the disc of a Finn cham-
ber (Epitest, Tuusula, Finland). This was then applied to
an area of shaved skin on the back of a mouse. For each
course of sensitization, freshly prepared patches were
applied daily from days 1 to 5. For pretreatment, mice
received a subcutaneous (s.c.) injection of 100 g BSA
emulsified in CFA over the bilateral side of tail-base or an
intraperitoneal (i.p.) injection of 100 g BSA in alum
adjuvant three weeks before sensitization.
Adoptive transfer
For adoptive transfer of OVA-TCR CD4 T cells, spleen cells
from DO.11.10 mice were positively selected for CD4 T
cells using CD4 microbeads. Then, 107 CD4 T cells/ml
were incubated with 1 M CFSE for 10 min at 37°C. Pre-
warmed FCS-containing PBS was added and washed by
cold PBS. Labeled OVA-TCR CD4 T cells (5 × 106) were
intravenously injected into BALB/c recipients 24 h before
sensitization.
LN and spleen cell cytokine production and proliferation 
assay
Ten days after the start of a sensitization course, mice were
sacrificed to obtain axillary, subscapular, and inguinal
LNs. Pooled LN cells (1 × 106) were cultured in the pres-Page 2 of 8
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harvested 48 h later and stored at -80°C. IFN-, IL-4, IL-5,
and IL-13 content of supernatants was each measured by
a standard sandwich ELISA. The limit of detection for IL-
4, IL-5, and IL-13 were all 10 pg/ml, whereas that for IFN-
 was 50 pg/ml. For spleen cells, spleens were harvested 3
weeks after sensitization, and pooled spleen cells were
stimulated with 100 g/ml OVA. For the proliferation
assay, graded doses of OVA were added. 48 h after the ini-
tiation of culture, [3H] thymidine was added and the cells
were harvested 18 h later.
Total RNA extraction, cDNA preparation and quantitative 
real-time PCR
The patched skin and draining lymph node samples were
obtained 24, 48, and 72 h after patch co-administration of
BSA and OVA. They were frozen with liquid nitrogen and
soaked in 1 ml TRIzol Reagent (Invitrogen, Carlsbad, CA,
USA). After homogenization, the total RNA was extracted,
cDNA was synthesized, and quantitative real-time PCR
was performed according to the manufacturer's instruc-
tions. Each sample was analyzed in triplicate. The relative
cytokine mRNA expression level of each sample was nor-
malized according to its -actin expression.
Results
Antigen-driven bystander effect enhances epicutaneously-
induced Th2 immune response to a co-administered new 
protein allergen
Murine protein-patch model has been established by us
and others to study immune responses induced by epicu-
taneous sensitization with protein antigens [12,14]. It has
been shown in previous studies that patch application of
OVA solution onto mouse skin induces a predominant
Th2 and a weak Th1 immune response. To investigate
whether polarized Th2 cells could influence the immune
response induced by epicutaneous sensitization with a
newly introduced protein antigen, mice were immunized
with BSA emulsified in alum adjuvant through the intra-
peritoneal route and were exposed to both OVA and BSA
epicutaneously by patch application three weeks later.
Data in Fig. 1A show that LN cells from mice previously
immunized with BSA and restimulated with OVA pro-
duced significantly higher IL-4, IL-5, and IL-13 in the cul-
ture supernatants as compared with cells from mice that
did not receive BSA immunization. There was no differ-
ence in IFN- production between mice receiving immu-
nization and those that did not. Interestingly, when BSA
was omitted from the patch, the enhanced Th2 response
Antigen-driven bystander effect by Th2 pretreatment enhanced epicutaneously induced Th2 immune response to a new pro-tein antigenFigure 1
Antigen-driven bystander effect by Th2 pretreatment enhanced epicutaneously induced Th2 immune 
response to a new protein antigen. Groups of mice (four per group) were non-pretreated (PBS, no), or intraperitoneally 
(ip) pretreated with BSA and alum adjuvant on day -21. They were all epicutaneously sensitized with BSA and OVA (no, ip) or 
PBS (PBS) on day 1–5. On day 11, draining LNs were obtained (A). On day 22, spleens were taken (B). In vitro reactivation cul-
ture with OVA was performed. Cytokine contents of 48 h-supernatants were measured by ELISA. Results were shown as 
mean ± SEM. Four independent experiments were performed with similar results. One representative results are shown.Page 3 of 8
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indicate that enhanced Th2 cytokine production was
induced by antigen-driven bystander effect. We further
tested whether spleen cells also mounted an enhanced
Th2-dominant response at a later time point. Splenocytes
from mice immunized with BSA and sensitized epicutane-
ously with OVA and BSA were restimulated with OVA. Fig.
1B shows that splenocyte IL-5 and IL-13 productions were
much higher than those from the mice without immuni-
zation. However, OVA-specific IL-4 production was not
detected in the spleen cell cultures. Next, we tested the
antigen-driven bystander effect of polarized Th1 cells.
Subcutaneous injection of protein antigen emulsified in
CFA adjuvant is a standard way to induce Th1-predomi-
nant immune response in experimental murine system.
BALB/c mice were immunized subcutaneously with BSA
emulsified in CFA or not three weeks before epicutaneous
sensitization with OVA plus BSA. LN cells from mice
receiving subcutanous immunization of BSA and patch-
sensitized with BSA and OVA produced not only higher
concentrations of IFN-, but also IL-4, IL-5 and IL-13 in
the culture supernatants after restimulation with OVA as
compared to cells from unimmunized mice (Fig. 2A). In
the meantime, the splenocyte IL-5 and IL-13 but not IFN-
 productions were much higher than those from the mice
without immunization (Fig. 2B). Mice immunized subcu-
taneously also had higher levels of serum OVA-specific
IgG2a and IgE in the serum (Fig. 2C) than the mice with-
out immunization, although they did not reach statistical
significance. As shown in Fig. 2D, subcutaneous immuni-
zation with BSA in CFA adjuvant induced both Th1 and
Th2 immune responses, indicated by high concentrations
of IFN- as well as significant amounts of IL-4, IL-5, and
IL-13. Taken together, despite its Th1/Th2 predominant
nature, the antigen-driven bystander effect enhances the
Th2 immune response induced by an epicutaneously
introduced new protein antigen.
Antigen-driven bystander effect decreases the threshold of 
epicutaneous sensitization with a new protein allergen
The next question was whether the antigen-driven
bystander effect could modulate the threshold of epicuta-
neous sensitization with a new protein allergen. LN cells
from mice receiving subcutaneous or intraperitoneal
immunization with BSA had higher proliferative response
to OVA after patch sensitization with both BSA and OVA
as compared with those without immunization (Fig. 3A).
Next, serial dilutions of OVA were co-administered with a
fixed concentration of BSA to explore whether immuniza-
tion modulates the threshold of epicutaneous sensitiza-
tion to OVA in this model system. LN cells from mice
subcutaneously immunized with BSA had higher prolifer-
ative response to OVA than mice without immunization
when OVA was co-administered at concentrations of 100
mg/ml, 10 mg/ml or 1 mg/ml with BSA. Without immu-
nization, OVA co-administered at 100 mg/ml and 10 mg/
ml but not at 1 mg/ml with BSA induced cells to respond
specifically to OVA stimulation (Fig. 3B). To examine
CD4 T cell proliferation in vivo, CD4 T cells from naïve
OVA-TCR transgenic mice (DO11.10) were labeled with
CFSE and intravenously transferred into BALB/c mice one
day before they received patch co-sensitization with OVA
and BSA. Fig. 3C shows that transgenic CD4 T cells prolif-
erated in mice subcutaneously immunized with BSA and
sensitized epicutaneously with 10 mg/ml and 100 mg/ml
OVA plus BSA, and adoptively transferred transgenic CD4
T cells had proliferative response only in unimmunized
mice patched with 100 mg/ml OVA (Fig. 3C). Collec-
tively, these data support the notion that the antigen-
driven bystander effect decreases the threshold of epicuta-
neous sensitization with a new protein allergen by at least
one order of magnitude.
The role of cytokines in epicutaneously induced antigen-
driven bystander effect
Among the cytokines that influence the Th1/Th2 balance,
IFN-, IL-12 and IL-18 are the key cytokines to induce Th1
responses, while IL-4, IL-10 and IL-13 preferentially prime
Th2 responses. Figure 4 shows that mice receiving subcu-
taneous immunization had higher levels of IL-4 and IL-10
expression in their draining LNs as early as 24 h after
patch sensitization as compared with mice without
immunization. The expressions of other cytokines,
including IL-5, IL-12, IL-13, IL-18, IFN- and TNF-, in the
draining LNs were similar in mice with or without immu-
nization. It is noteworthy, the expressions of all of these
cytokines in the patch-applied skin were not different
between mice with or without immunization groups
(data not shown). Taken together, these results suggest
that immunization-induced IL-4 and IL-10 expression
contributes to the epicutaneously induced antigen-driven
bystander effect.
Discussion
The data presented here clearly demonstrate that the anti-
gen-driven bystander effect, despite its Th1- or Th2-pre-
dominant nature, accelerates epicutaneous sensitization
with a new protein allergen by enhancing the Th2
immune response and by lowering the sensitization
threshold. To our knowledge, this is the first report to
address the contribution of antigen-driven bystander
effect to the epicutaneous sensitization of protein aller-
gens in atopic disease.
The continuation of fetal allergen-specific Th2 responses
associated with decreased capacity to produce Th1
cytokine IFN- is a defining feature of atopic disease in
infancy [25]. After infancy, the major sensitized allergens
shift from oral food allergens to aeroallergens [26]. Sev-
eral observations are consistent with the view that somePage 4 of 8
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Antigen-driven bystander effect by Th1 pretreatment also enhanced epicutaneously induced Th2 immune response to a new protei  antigFigure 2
Antigen-driven bystander effect by Th1 pretreatment also enhanced epicutaneously induced Th2 immune 
response to a new protein antigen. (A) (B) (C) Group of mice (Four per group) were non-pretreated (PBS, no) or subcu-
taneously (sc) pretreated with BSA and CFA adjuvant on day -21. They were all epicutaneously sensitized with BSA and OVA 
(no, sc) or PBS (PBS) on day 1–5. On day 11, draining LNs were obtained (A). On day 22 spleens were taken (B). In vitro reac-
tivation culture with OVA was performed. Cytokines contents of 48 h-supernatants were measured by ELISA. Results were 
shown as mean ± SEM. (C) On day 22~26, all mice received another course of OVA patch application. On day 29, blood were 
collected and serum OVA-specific IgG2a and IgE were determined by ELISA. Three independent experiments were performed 
with similar results. One representative results are shown. (D) Groups of mice (four per group) were immunized by subcuta-
neous injection with BSA and CFA adjuvant (sc) or BSA and alum adjuvants (ip) three weeks before their spleens were 
obtained. In vitro reactivation culture of spleen cells with BSA was performed. Cytokine contents of 48 h-supernatants were 
measured by ELISA. Results were shown as mean ± SEM. Three independent experiments were performed with similar results. 
One representative results are shown.
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sitization. Firstly, the dose-response relationship between
allergen exposure and sensitization differs depending on
allergens and locales [27]. Secondly, once sensitized to
one allergen, atopic patients are more likely to become
sensitized to other allergens [28]. Moreover, there are
strong associations of multiple sensitizations both within
and between different allergen classes [28]. Skin is contin-
uously exposed to many kinds of allergens and microor-
ganisms in the environment. Microorganisms can gain
access to the human body through different routes and
sensitize the immune system before contact with the skin.
Therefore, it is very likely that the antigen-driven
bystander effect affects our skin constantly, although its
effect may vary. Thus, the present study provides a possi-
ble mechanistic explanation to the clinical observation of
the spread of Th2 responses from mono-allergen to mul-
tiple allergens in atopic individuals. Another clinical
implication of our data is that our results do not conflict
with "hygiene hypothesis". The "hygiene hypothesis" pre-
dicts that nonspecific suppression of Th2 immune
response by a predominant systemic Th1 milieu at the
time of sensitization prevents the development of allergy.
However, our present study demonstrated specific, but
not non-specific, promotion of Th2 immune responses by
antigen-driven bystander effect. Collectively, our results
support the wisdom of recognizing allergen sensitization
early in life and taking precautions to prevent exposure of
skins to these allergens.
The mechanism underlying the antigen-driven bystander
effect is still obscure. Alpan et al. suggests that orally
induced memory T cells utilize IL-4 and IL-10 they pro-
duced, but not CD40 ligand, to educate DCs which in turn
induce conversion of naïve T cells [23]. However, since co-
culturing DCs with naïve T cells plus various concentra-
tions of IL-4 and IL-10 does not simulate the situation in
which DC was educated by orally induced memory T cells
in their studies, the authors suggested that there must be
other factors involved [23]. Our current study provides
more information about the underlying mechanism of
antigen-driven bystander effect. As we demonstrated in
this report, systemic immunization plus skin sensitization
to protein antigens induce increased cytokine expression
in the draining LNs, but not in the patched skin. This
observation supports the notion that the draining LNs are
the site where antigen-driven bystander effect takes place
[29].
In summary, in this study we demonstrated that antigen-
driven bystander effect contributes to accelerated epicuta-
neous sensitization with a new protein allergen. These
results provide a possible explanation for a mono- to
poly-sensitization spread commonly observed in atopic
children.
Influence of antigen-driven bystander effect on the threshold of epicutaneous sensitization with a n w pr tein allergenFigure 3
Influence of antigen-driven bystander effect on the 
threshold of epicutaneous sensitization with a new 
protein allergen. (A) Groups of mice (four per group) 
were similarly pretreated and immunized as in Fig. 1 (A). On 
day 11, draining LNs were obtained and OVA-specific prolif-
eration assay was performed. (B) Groups of mice (four per 
group) were subcutaneously pretreated with BSA (sc) or not 
(no) on day -21. They received patch co-administration of 
serial dilutions of OVA (100, 10, 1 mg/ml) and BSA (100 mg/
ml) on day 1–5. On day 11, draining LNs were obtained and 
OVA-specific proliferation assay was performed. (C) Groups 
of mice (four per group) were non-pretreated (no) or subcu-
taneously (sc) pretreated on day -21. One day before patch 
application, all mice received i.v. transfer of CFSE-labeled 
CD4 T cells prepared from DO11.10 transgenic mice. Patch 
application with serial dilutions of OVA (100, 10, 1 mg/ml) 
and BSA (100 mg/ml) were performed on day 1–3. Regional 
LNs were obtained on day 4 for staining and flow cytometric 
analysis. All experiments were performed independently for 
at least three times. One representative results are shown.Page 6 of 8
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The role of cytokine in the epicutaneously induced antigen-driven bystander effectFigu e 4
The role of cytokine in the epicutaneously induced antigen-driven bystander effect. Groups of mice (three per 
group) were non-pretreated (no) or pretreated subcutaneously with BSA and CFA adjuvant (sc) three weeks before they 
received patch sensitization with OVA and BSA on day 1–3. Draining LNs were obtained 24, 48 and 72 hr after start of patch 
sensitization. Total RNA extraction, cDNA preparation and quantitative real-time PCR were performed individually. The rela-
tive cytokine mRNA expression levels of each sample were normalized according to its -actin expression. Results are shown 
as mean ± SEM. Three independent experiments were performed with similar results. One representative results are shown.
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